THERAPEUTIC MONITORING OF ANTIPSYCHOTIC DRUGS

Chromatography

THERAPEUTIC MONITORING OF ANTIPSYCHOTIC DRUGS

05 Nov, 2008

Published over 17 years ago. See the latest and most current information on Chromatography.

Dr Bob Flanagan
1 min read
Download
Nowadays the mainstay of treatment is drug therapy. Chlorpromazine, haloperidol and other ‘first generation’ drugs are gradually being superseded by ‘second generation’ or ‘atypical’ antipsychotics that generally have fewer unpleasant side-effects than the older drugs. The most effective of these second generation drugs is clozapine. There are a number of reports that demonstrate relationships between plasma antipsychotic concentrations and in vivo binding to receptors in different regions of the brain. However, only in the case of plasma clozapine is there evidence that there is a generallyapplicable ‘target range’ associated with successful therapy making it an ideal candidate for therapeutic drug monitoring (TDM) (Flanagan, 2006; Hiemke, 2008).

Latest Articles

ILM Guide 2026/27

Explore our Digital Edition

Discover the latest news and research

Digital edition

Explore Our Other Sites

Envirotech Online
EU ETS benchmark update puts industrial emissions data under sharper scrutiny
Explore more Arrow
Pollution Solutions Online
DNV introduces new framework for measuring onboard carbon capture performance
Explore more Arrow
Petro Online
New test method ASTM D8606 has been officially released
Explore more Arrow
Chromatography Today
Non-invasive flowmeters for real-time monitoring
Explore more Arrow